CSL Ltd Annual Report 2021

Table 3: STI Outcomes in 2021 Executive Value of STI Earned US$ STI opportunity at Target level hurdle as a % of FR STI opportunity at Maximum level hurdle as a % of FR Target STI earned as % of opportunity STI earned as % of Maximum opportunity 6 STI earned as % of FR Financial Performance Outcome Individual Performance Outcome P Perreault 1,807,032 120% 180% 86% 57% 103% Between Target and Maximum Between Threshold and Target J Linton 288,464 85% 128% 113% 75% 31% Between Target and Maximum Between Threshold and Target P McKenzie 1,028,970 100% 150% 108% 72% 108% Between Target and Maximum Between Threshold and Target 6 Any STI that was not earned was automatically forfeited. 6.2.1 CEO 2021 STI Achievement and Outcome The Board considered the following highlights when determining the STI outcome for Mr Perreault. Table 4: CEO STI Outcomes in 2021 Measure and commentary Weight Threshold 50% Target 100% Maximum 150% % of maximum opportunity Financials • Solid NPAT result against target – reported NPAT of US$2,375.0m • Strong CFO outcome significantly exceeding target – reported CFO of US$3,621.9m 35% 25% 68.3% 100% Stabilise plasma business fundamentals and return to sustainable growth • Challenging plasma collection levels however multiple initiatives are driving solid growth • Most major capital projects on target • Organisational transformation of ‘Enabling Functions’ on target with enterprise operating models in place 20% 0% Deliver growth options and build a robust pipeline of safe and effective life-saving medicines • Successful integration of acquisitions • COVID-19 collaboration initiatives undertaken (e.g. UQ vaccine, COVID-19 hyper-immune and COVID-19 related respiratory distress) • Restart and reset of ongoing clinical trials delayed due to COVID-19 priorities – revised timelines and milestones in place 10% 43.3% People and Culture • Renewal of executive leadership team and portfolios complete including all key appointments filled • Strengthened leadership pipeline in place • Improvement in all safety metrics over prior year – TRIFR improvement across most locations with enhanced near miss reporting and closeout processes and actions 10% 43.3% ● ● ● ● ● CSL Limited Annual Report 2020/21 87